LivaNova PLC has announced that it will present eight scientific posters at the upcoming American Epilepsy Society $(AES)$ Annual Meeting, scheduled for December 5-9 in Atlanta. The presentations will showcase real-world evidence from the CORE-VNS study, described as the largest prospective, multinational observational study of VNS Therapy for Drug-Resistant Epilepsy $(DRE)$, as well as new health economics analyses. Among the topics to be presented are healthcare resource use and costs before and after VNS Therapy implantation across different U.S. payer types, with findings indicating reductions in hospitalizations, emergency department visits, and overall costs following VNS Therapy. The results will be available to conference attendees during the meeting, and abstracts and posters will also be accessible on the AES website during and after the congress.